A detailed history of Stone X Group Inc. transactions in Novartis Ag stock. As of the latest transaction made, Stone X Group Inc. holds 2,224 shares of NVS stock, worth $290,832. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,224
Previous 4,085 45.56%
Holding current value
$290,832
Previous $466 Million 42.29%
% of portfolio
0.01%
Previous 0.19%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025

SELL
$101.96 - $121.01 $189,747 - $225,199
-1,861 Reduced 45.56%
2,224 $269 Million
Q1 2025

Aug 13, 2025

BUY
$97.14 - $115.57 $179,029 - $212,995
1,843 Added 82.2%
4,085 $466 Million
Q4 2024

Aug 13, 2025

BUY
$96.78 - $117.18 $216,980 - $262,717
2,242 New
2,242 $218 Million
Q4 2023

Aug 13, 2025

BUY
$92.27 - $101.54 $201,886 - $222,169
2,188 New
2,188 $221 Million
Q3 2023

Aug 13, 2025

SELL
$94.73 - $105.13 $33,060 - $36,690
-349 Reduced 13.25%
2,285 $233 Million
Q2 2023

Aug 13, 2025

BUY
$92.52 - $104.91 $243,697 - $276,332
2,634 New
2,634 $266 Million
Q1 2023

Aug 13, 2025

BUY
$80.03 - $92.81 $189,190 - $219,402
2,364 New
2,364 $217 Million
Q2 2022

Aug 13, 2025

SELL
$80.52 - $93.75 $323,046 - $376,125
-4,012 Reduced 53.85%
3,439 $291 Million
Q1 2022

Aug 13, 2025

BUY
$80.11 - $90.62 $596,899 - $675,209
7,451 New
7,451 $654 Million
Q4 2021

Feb 10, 2022

SELL
$79.7 - $88.13 $8.38 Million - $9.27 Million
-105,169 Closed
0 $0
Q3 2021

Oct 20, 2021

BUY
$81.78 - $95.14 $8.6 Million - $10 Million
105,169 New
105,169 $8.6 Million
Q3 2017

Nov 13, 2017

SELL
$74.14 - $77.27 $1.65 Million - $1.72 Million
-22,265 Closed
0 $0
Q2 2017

Aug 31, 2017

BUY
N/A
22,265
22,265 $1.86 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $281B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.